metformin has been researched along with Edema in 16 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Edema: Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3." | 9.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
| "Metformin injections elevated von Frey thresholds (reduced mechanical allodynia) in complex regional pain syndrome mice versus saline-treated fracture mice between days 25 and 56 (difference of mean area under the curve, 42." | 7.96 | Early Treatment With Metformin in a Mice Model of Complex Regional Pain Syndrome Reduces Pain and Edema. ( Buvanendran, A; Das, V; Kroin, JS; McCarthy, RJ; Moric, M, 2020) |
| "Metformin is an oral hypoglycemic drug widely used in the management of type 2 diabetes mellitus." | 5.72 | Metformin effect in models of inflammation is associated with activation of ATP-dependent potassium channels and inhibition of tumor necrosis factor-α production. ( Augusto, PSA; Batista, CRA; Bertollo, CM; Braga, AV; Coelho, MM; Costa, SOAM; Dutra, MMGB; Machado, RR; Matsui, TC; Melo, ISF; Morais, MI; Rodrigues, FF, 2022) |
| " Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3." | 5.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
| " Vildagliptin provided additional HbA(1c) lowering to that achieved with metformin alone and comparable to that achieved with pioglitazone, with only pioglitazone causing weight gain." | 5.14 | Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. ( Bolli, G; Colin, L; Dotta, F; Goodman, M; Minic, B, 2009) |
| "Metformin injections elevated von Frey thresholds (reduced mechanical allodynia) in complex regional pain syndrome mice versus saline-treated fracture mice between days 25 and 56 (difference of mean area under the curve, 42." | 3.96 | Early Treatment With Metformin in a Mice Model of Complex Regional Pain Syndrome Reduces Pain and Edema. ( Buvanendran, A; Das, V; Kroin, JS; McCarthy, RJ; Moric, M, 2020) |
| "Pioglitazone was associated with a significant increase in body weight and edema." | 3.75 | Adverse effect of pioglitazone in military personnel and their families: a preliminary report. ( Benjasuratwong, Y; Patarakitvanit, S; Satyapan, N; Temboonkiat, S; Vudhironarit, T, 2009) |
| "At 26 wk, edema was recorded in 48 of the patients (14%) treated with ragaglitazar, and Cox regression analyses identified the common Pro12Ala variant of the PPARG gene as biologically the most important risk factor (hazard ratio 4." | 2.72 | The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. ( Anant, M; Ekstrøm, CT; Hansen, L; Reinhardt, RR; Tabanera Y Palacios, R; Wassermann, K, 2006) |
| "Metformin is an oral hypoglycemic drug widely used in the management of type 2 diabetes mellitus." | 1.72 | Metformin effect in models of inflammation is associated with activation of ATP-dependent potassium channels and inhibition of tumor necrosis factor-α production. ( Augusto, PSA; Batista, CRA; Bertollo, CM; Braga, AV; Coelho, MM; Costa, SOAM; Dutra, MMGB; Machado, RR; Matsui, TC; Melo, ISF; Morais, MI; Rodrigues, FF, 2022) |
| "The insulin-induced edema is a rare complication of insulin therapy." | 1.46 | Insulin-induced edema: an unusual complication in a patient with diabetic ketosis. ( Chaker, F; Chihaoui, M; Rached, A; Slimane, H; Yazid, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Augusto, PSA | 1 |
| Matsui, TC | 1 |
| Braga, AV | 1 |
| Rodrigues, FF | 1 |
| Morais, MI | 1 |
| Dutra, MMGB | 1 |
| Batista, CRA | 1 |
| Melo, ISF | 1 |
| Costa, SOAM | 1 |
| Bertollo, CM | 1 |
| Coelho, MM | 1 |
| Machado, RR | 1 |
| Aung, TKK | 1 |
| Chuah, TY | 1 |
| Chua, MWJ | 1 |
| Chaker, F | 1 |
| Yazid, M | 1 |
| Chihaoui, M | 1 |
| Rached, A | 1 |
| Slimane, H | 1 |
| Das, V | 1 |
| Kroin, JS | 1 |
| Moric, M | 1 |
| McCarthy, RJ | 1 |
| Buvanendran, A | 1 |
| Zhou, K | 1 |
| Pedersen, HK | 1 |
| Dawed, AY | 1 |
| Pearson, ER | 1 |
| Pandey, A | 1 |
| Kumar, VL | 1 |
| Soudet, S | 1 |
| Lambert, M | 1 |
| Lefèvre, G | 1 |
| Maillard, H | 1 |
| Huglo, D | 1 |
| Hatron, PY | 1 |
| Bolli, G | 1 |
| Dotta, F | 1 |
| Colin, L | 1 |
| Minic, B | 1 |
| Goodman, M | 1 |
| Vudhironarit, T | 1 |
| Benjasuratwong, Y | 1 |
| Patarakitvanit, S | 1 |
| Temboonkiat, S | 1 |
| Satyapan, N | 1 |
| Silva, DC | 1 |
| Freitas, AL | 1 |
| Pessoa, CD | 1 |
| Paula, RC | 1 |
| Mesquita, JX | 1 |
| Leal, LK | 1 |
| Brito, GA | 1 |
| Gonçalves, DO | 1 |
| Viana, GS | 1 |
| Samson, SL | 1 |
| Sathyanarayana, P | 1 |
| Jogi, M | 1 |
| Gonzalez, EV | 1 |
| Gutierrez, A | 1 |
| Krishnamurthy, R | 1 |
| Muthupillai, R | 1 |
| Chan, L | 1 |
| Bajaj, M | 1 |
| Reyes-Morales, H | 1 |
| Mino-León, D | 1 |
| Doubova, SV | 1 |
| Flores-Hernández, S | 1 |
| Ragia, G | 1 |
| Manolopoulos, VG | 1 |
| Nesto, RW | 1 |
| Bell, D | 1 |
| Bonow, RO | 1 |
| Fonseca, V | 1 |
| Grundy, SM | 1 |
| Horton, ES | 1 |
| Le Winter, M | 1 |
| Porte, D | 1 |
| Semenkovich, CF | 1 |
| Smith, S | 1 |
| Young, LH | 1 |
| Kahn, R | 1 |
| Hansen, L | 1 |
| Ekstrøm, CT | 1 |
| Tabanera Y Palacios, R | 1 |
| Anant, M | 1 |
| Wassermann, K | 1 |
| Reinhardt, RR | 1 |
| Valensi, P | 1 |
| Behar, A | 1 |
| Andre, P | 1 |
| Wiernsperger, N | 1 |
| Attali, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus[NCT01432405] | Phase 4 | 24 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride. A Double-blind Placebo Controlled Cross Over Study.[NCT00285805] | 13 participants (Actual) | Interventional | 2006-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The effect of exenatide and pioglitazone on liver fat content after one year of treatment in patients with type 2 diabetes. (NCT01432405)
Timeframe: one year
| Intervention | percent of liver fat (Mean) |
|---|---|
| Pioglitazone and Exenatide | 4.7 |
| Pioglitazone | 6.5 |
the effect of the intervention on plasma adiponectin levels. (NCT01432405)
Timeframe: one year
| Intervention | microgram per ml (Mean) |
|---|---|
| Pioglitazone and Exenatide | 23.2 |
| Pioglitazone | 15.8 |
2 reviews available for metformin and Edema
| Article | Year |
|---|---|
Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Drug Discovery; Drug-Related Side | 2016 |
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
Topics: Blood Volume; Clinical Trials as Topic; Comorbidity; Contraindications; Diabetes Mellitus, Type 2; D | 2003 |
3 trials available for metformin and Edema
| Article | Year |
|---|---|
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptid | 2009 |
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Topics: Adult; Aged; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, | 2011 |
The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; DNA; Edema; Female; Genetic Predisposition to Disease; Genotype; Glyburid | 2006 |
11 other studies available for metformin and Edema
| Article | Year |
|---|---|
Metformin effect in models of inflammation is associated with activation of ATP-dependent potassium channels and inhibition of tumor necrosis factor-α production.
Topics: Adenosine Triphosphate; Animals; Carrageenan; Diabetes Mellitus, Type 2; Disease Models, Animal; Ede | 2022 |
More Than Meets the Eye: A Patient with Hand Swelling and Newly Diagnosed Diabetes Mellitus.
Topics: Aged; Amlodipine; Anemia; Antihypertensive Agents; Blood Sedimentation; C-Reactive Protein; Diabetes | 2021 |
Insulin-induced edema: an unusual complication in a patient with diabetic ketosis.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Edema; Humans; Insulin; Male; Metformin | 2017 |
Early Treatment With Metformin in a Mice Model of Complex Regional Pain Syndrome Reduces Pain and Edema.
Topics: Animals; Complex Regional Pain Syndromes; Disease Models, Animal; Edema; Female; Hypoglycemic Agents | 2020 |
Protective Effect of Metformin against Acute Inflammation and Oxidative Stress in Rat.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Carrageenan; Catalase; Diclofenac; Disease Models, | 2016 |
Long term use of metformin in idiopathic cyclic edema, report of thirteen cases and review of the literature.
Topics: Adult; Aged; Capillary Permeability; Diarrhea; Edema; Female; Humans; Hypoglycemic Agents; Male; Met | 2017 |
Adverse effect of pioglitazone in military personnel and their families: a preliminary report.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Edema; Family; Female; Humans; Hypoglycemic Agents; Incidenc | 2009 |
Pectin from Passiflora edulis shows anti-inflammatory action as well as hypoglycemic and hypotriglyceridemic properties in diabetic rats.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Biomarkers; Ca | 2011 |
Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Drug Combinations; Edema; Female; Foll | 2012 |
Highlights from the latest articles in diabetes pharmacogenomics.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2012 |
The effects of metformin on the capillary permeability to albumin in women patients with cyclic edema.
Topics: Adult; Albumins; Capillary Permeability; Edema; Female; Humans; Metformin; Middle Aged; Obesity | 1995 |